FDA to Launch Next Generation CTP Portal Next Year

Regulations by 2FIRSTS.ai
Jul.16.2024
FDA to Launch Next Generation CTP Portal Next Year
FDA to launch new CTP portal for tobacco product applications next year, streamlining submission process for SE and PMTA reports.

On July 15th, the Center for Tobacco Products (CTP) of the US Food and Drug Administration (FDA) published two notices in the Federal Register, stating their plans to launch a new generation CTP web portal next year for the submission of certain new tobacco product applications.


The purpose of this improvement is:


Integration of major Substantial Equivalence (SE) reports and Premarket Tobacco Product Applications (PMTAs), previously submitted amendments, and general correspondence into one system; introducing a more efficient submission process by eliminating the need for multiple tools (including consolidating PDF editing software, FDA's eSubmitter desktop tool, and FDA's CTP Portal web application into one place); providing tools to expedite data entry, guide applicants to relevant sections, and verify that all necessary data has been provided. No action is required for current users of any CTP system for these improvements in the works. Existing CTP Portal accounts and any pending or ongoing applications will automatically migrate to the new CTP Portal Next Generation. CTP will provide additional communication and support before the changes take effect.


As part of submitting SE reports and PMTAs in the CTP Portal Next Generation, applicants will need to enter certain information on the applicable forms. Therefore, two Federal Register notices (one regarding SE, one regarding PMTA) announced today are seeking public input on entering this information.


The public comment period will begin on July 16 and end on September 14 at 11:59 PM (Eastern Time).


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Jeju Health Center to Apply Conventional Tobacco Rules to Liquid E-Cigarettes From April 24
Jeju Health Center to Apply Conventional Tobacco Rules to Liquid E-Cigarettes From April 24
Jeju Health Center said it will apply the same regulations used for conventional tobacco products to all tobacco products, including liquid e-cigarettes, from April 24, while also strengthening public guidance and smoke-free zone management.
Apr.21 by 2FIRSTS.ai
State Attorneys General Urge Visa, Mastercard and Others to Stop Processing Illicit E-Cigarette Transactions
State Attorneys General Urge Visa, Mastercard and Others to Stop Processing Illicit E-Cigarette Transactions
Fourteen U.S. state attorneys general sent a joint letter dated April 14, 2026 to Visa, Mastercard, American Express and Discover, asking them to immediately help stop the sale of illicit e-cigarette products by cutting off payment access.
Apr.17 by 2FIRSTS.ai
Philippine Anti-Smoking Groups Urge DTI Action Over Alleged Vape Law Violations by ZYN and IQOS
Philippine Anti-Smoking Groups Urge DTI Action Over Alleged Vape Law Violations by ZYN and IQOS
Several anti-smoking and health advocacy groups in the Philippines urged the Department of Trade and Industry to take action against tobacco companies accused of violating the Vape Regulation Act of 2022. The groups said three consecutive complaints had been filed involving nicotine pouch brand ZYN and heated tobacco product company IQOS Philippines.
Apr.27 by 2FIRSTS.ai
2Firsts Hosts U.S. Compliance Briefing on Building PMTA Support Capabilities Across the Nicotine Supply Chain
2Firsts Hosts U.S. Compliance Briefing on Building PMTA Support Capabilities Across the Nicotine Supply Chain
2Firsts held a U.S. compliance briefing in Shenzhen to help vaping, heated tobacco and nicotine pouch supply chain companies strengthen PMTA support capabilities. The event focused on supplier documentation, quality systems, traceability, TPMF/TPMP pathways, age verification and customer audit readiness as U.S. compliance expectations increasingly extend deeper into the nicotine supply chain.
Events
Jun.12
Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS
Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS
Altria Group reported its first-quarter 2026 results on April 30. Net revenues were $5.43 billion, up 3.2% year on year, while revenues net of excise taxes were $4.76 billion, up 5.3%. Reported diluted EPS was $1.30, up more than 100%, and adjusted diluted EPS was $1.32, up 7.3%.
May.06 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13